When Is Stratification Detrimental to a Clinical Trial Design? Part II Katherine L. Monti, Ph.D. Senior Statistical Scientist and Director of the Massachusetts.

Slides:



Advertisements
Similar presentations
FDA/Industry Workshop September, 19, 2003 Johnson & Johnson Pharmaceutical Research and Development L.L.C. 1 Uses and Abuses of (Adaptive) Randomization:
Advertisements

COMPUTER INTENSIVE AND RE-RANDOMIZATION TESTS IN CLINICAL TRIALS Thomas Hammerstrom, Ph.D. USFDA, Division of Biometrics The opinions expressed are those.
Multiple Comparisons in Factorial Experiments
Stratification (Blocking) Grouping similar experimental units together and assigning different treatments within such groups of experimental units A technique.
Why to Randomize a Randomized Controlled Trial? (and how to do it) John Matthews University of Newcastle upon Tyne.
Chapter 5 Producing Data
Controlling the Experimentwise Type I Error Rate When Survival Analyses Are Planned for Subsets of the Sample. Greg Yothers, MA National Surgical Adjuvant.
Cox Model With Intermitten and Error-Prone Covariate Observation Yury Gubman PhD thesis in Statistics Supervisors: Prof. David Zucker, Prof. Orly Manor.
Stratified Randomization in Clinical Trials Katherine L. Monti, Ph.D. Senior Statistical Scientist and Director of the Massachusetts Office, Rho, Inc.
Point and Confidence Interval Estimation of a Population Proportion, p
Chapter 3 Analysis of Variance
Meta-analysis & psychotherapy outcome research
Incomplete Block Designs
Inferences About Process Quality
McGraw-Hill-Ryerson © The McGraw-Hill Companies, Inc., 2004 All Rights Reserved. 7-1 Chapter 7 Chapter 7 Created by Bethany Stubbe and Stephan Kogitz.
Sample Size Determination
Frank Mannino1 Richard Heiberger2 Valerii Fedorov1
Introduction to the design (and analysis) of experiments James M. Curran Department of Statistics, University of Auckland
Difference Two Groups 1. Content Experimental Research Methods: Prospective Randomization, Manipulation Control Research designs Validity Construct Internal.
Chapter 5 Data Production
Testing People Scientifically.  Clinical trials are research studies in which people help doctors and researchers find ways to improve health care. Each.
Chapter 8 Introduction to Hypothesis Testing
Experimental Design making causal inferences Richard Lambert, Ph.D.
Optimal cost-effective Go-No Go decisions Cong Chen*, Ph.D. Robert A. Beckman, M.D. *Director, Merck & Co., Inc. EFSPI, Basel, June 2010.
Assessing ETA Violations, and Selecting Attainable/Realistic Parameters Causal Effect/Variable Importance Estimation and the Experimental Treatment Assumption.
McGraw-Hill/Irwin Copyright © 2007 by The McGraw-Hill Companies, Inc. All rights reserved. Experimental Design and Analysis of Variance Chapter 10.
Biostatistics Case Studies 2007 Peter D. Christenson Biostatistician Session 3: Incomplete Data in Longitudinal Studies.
Part III Gathering Data.
1-1 Copyright © 2015, 2010, 2007 Pearson Education, Inc. Chapter 10, Slide 1 Chapter 10 Understanding Randomness.
Basics of Randomization.
Agresti/Franklin Statistics, 1 of 56  Section 4.3 What Are Good Ways and Poor Ways to Experiment?
Appraising Randomized Clinical Trials and Systematic Reviews October 12, 2012 Mary H. Palmer, PhD, RN, C, FAAN, AGSF University of North Carolina at Chapel.
Producing Data 1.
1 OTC-TFM Monograph: Statistical Issues of Study Design and Analyses Thamban Valappil, Ph.D. Mathematical Statistician OPSS/OB/DBIII Nonprescription Drugs.
Adaptive randomization
1 Statistics in Research & Things to Consider for Your Proposal May 2, 2007.
SAS Macro for Constrained Randomization: Balancing covariates in Group Randomized Trials Ashraf Chaudhary, Ph.D. & Larry Moulton, Ph.D. Department of International.
Sampling Sources: -EPIET Introductory course, Thomas Grein, Denis Coulombier, Philippe Sudre, Mike Catchpole -IDEA Brigitte Helynck, Philippe Malfait,
Single-Factor Studies KNNL – Chapter 16. Single-Factor Models Independent Variable can be qualitative or quantitative If Quantitative, we typically assume.
Principles of exp. design Control for effects of lurking variables Randomization to keep personal biases or other preferences out of the study Replication.
Experimentation in Computer Science (Part 2). Experimentation in Software Engineering --- Outline  Empirical Strategies  Measurement  Experiment Process.
© Copyright McGraw-Hill 2004
Hypothesis Testing Introduction to Statistics Chapter 8 Feb 24-26, 2009 Classes #12-13.
Biostatistics Basics: Part I Leroy R. Thacker, PhD Associate Professor Schools of Nursing and Medicine.
ICCS 2009 IDB Seminar – Nov 24-26, 2010 – IEA DPC, Hamburg, Germany Training Workshop on the ICCS 2009 database Weights and Variance Estimation picture.
When Is Stratification Detrimental to a Clinical Trial Design? Part I Gretchen Marcucci, M.S. Biostatistician, Rho, Inc. and Katherine L. Monti, Ph.D.
Handout Six: Sample Size, Effect Size, Power, and Assumptions of ANOVA EPSE 592 Experimental Designs and Analysis in Educational Research Instructor: Dr.
The Mixed Effects Model - Introduction In many situations, one of the factors of interest will have its levels chosen because they are of specific interest.
1 Pulminiq™ Cyclosporine Inhalation Solution Pulmonary Drug Advisory Committee Meeting June 6, 2005 Statistical Evaluation Statistical Evaluation Jyoti.
8- 1 Chapter Eight McGraw-Hill/Irwin © 2005 The McGraw-Hill Companies, Inc., All Rights Reserved.
1 Chapter 11 Understanding Randomness. 2 Why Random? What is it about chance outcomes being random that makes random selection seem fair? Two things:
Introduction to Biostatistics, Harvard Extension School, Fall, 2005 © Scott Evans, Ph.D.1 Sample Size and Power Considerations.
Outline of Stratification Lectures Definitions, examples and rationale (credibility) Implementation –Fixed allocation (permuted blocks) –Adaptive (minimization)
Chapter 8 Sampling Methods and the Central Limit Theorem.
1.3 Experimental Design. What is the goal of every statistical Study?  Collect data  Use data to make a decision If the process to collect data is flawed,
Chapter 4 Potpourri.
Chapter 5 Data Production
ANOVA Econ201 HSTS212.
Comparing Three or More Means
The 4th ICTMC & 38th Annual Meeting of SCT
Elaine M Pascoe, Darsy Darssan, Liza A Vergara
Comparing Several Means: ANOVA
Joanna Romaniuk Quanticate, Warsaw, Poland
Experimental Studies.
CHAPTER 11: Producing Data— Part II Review
Statistical Data Analysis
Handling Missing Not at Random Data for Safety Endpoint in the Multiple Dose Titration Clinical Pharmacology Trial Li Fan*, Tian Zhao, Patrick Larson Merck.
Warmup A drug company wants to test a new drug, statsium, to determine if it improves memory in young adults. There will be two treatments: a daily.
Dr. Arslan Ornek MATHEMATICAL MODELS
STATISTICS INFORMED DECISIONS USING DATA
Presentation transcript:

When Is Stratification Detrimental to a Clinical Trial Design? Part II Katherine L. Monti, Ph.D. Senior Statistical Scientist and Director of the Massachusetts Office, Rho, Inc. Adjunct Associate Professor, Biostatistics University of North Carolina Gretchen Marcucci, M.S. Biostatistician, Rho, Inc.

2  2003 Katherine L. Monti. All rights reserved. No part of this document may be copied without express written consent. Introduction The method of randomizing clinical trial subjects to treatments in the presence of a (possibly important) prognostic factor requires a design decision: –To stratify on the factor or not to stratify? –Preconception: “Stratification can’t hurt.” This paper assesses that preconception for a particular design problem.

3  2003 Katherine L. Monti. All rights reserved. No part of this document may be copied without express written consent. Outline Motivation for the assessment Description of the approach Results Conclusions

4  2003 Katherine L. Monti. All rights reserved. No part of this document may be copied without express written consent. Motivation A drug company’s design: –120 subjects – 4 treatments (placebo, three drug doses) – 30 sites – 1 prognostic factor with 2 levels (hi and low levels, continuous covariate) Randomization: –At each site, NOT centralized –In blocks of 4 within factor level within site

5  2003 Katherine L. Monti. All rights reserved. No part of this document may be copied without express written consent. Motivation Those designing the study thought that randomizing within level of the (prognostic ?) factor –would increase balance in the design –“couldn’t hurt” Others argued that randomizing within factor level would lead to –operational difficulties –greater imbalance in the design

6  2003 Katherine L. Monti. All rights reserved. No part of this document may be copied without express written consent. Operational Difficulties Drug supply requirements increased. (~ 33%) Packaging/shipping costs increased. Additional training visits to sites were needed in order to explain the more complex randomization scheme. The project management burden increased. The misassignment of subjects to treatment was more likely.

7  2003 Katherine L. Monti. All rights reserved. No part of this document may be copied without express written consent. Imbalance 120 subjects/ (30 sites) = 4 subjects per site Perfect balance with 4 treatments 120 subjects/ (30 sites x 2 level) = 2 subjects per site for each level Balance not assured with 4 treatments

8  2003 Katherine L. Monti. All rights reserved. No part of this document may be copied without express written consent. Imbalance Although 120/30 = 4 is the “expected” number of subjects per site, 4 subjects enrolling at each site is not really expected! –We don’t know what the real enrollment pattern will be, but we know that it is not likely to be exactly 4 subjects per site. Therefore we anticipate some overall treatment imbalance when randomizing within site. However, additionally restricting randomization to within level of the prognostic variable within site could only increase the imbalance.

9  2003 Katherine L. Monti. All rights reserved. No part of this document may be copied without express written consent. Simulation I set out to compare the magnitude of the treatment imbalance if randomization were performed in permuted blocks of 4: –within site (WS) (30 strata) –within level of the factor within site (WLWS) (60 strata) Used simulation.

10  2003 Katherine L. Monti. All rights reserved. No part of this document may be copied without express written consent. Simulation Used SAS PROC PLAN to generate treatment assignments in permuted blocks of 4 –for 30 sites and –for 30 sites with 2 factor levels per site

11  2003 Katherine L. Monti. All rights reserved. No part of this document may be copied without express written consent. Enrollment Patterns To compare the balance in treatment assignment when randomizing WS and WLWS, we need to assign subjects to treatments –at each site and then reassign –in each level at each site To assign subjects to treatments, we need to know the the number of subjects ( N ij ) –in site i (i=1-30) who have –factor level j (j=1,2) The N ij are unknown….

12  2003 Katherine L. Monti. All rights reserved. No part of this document may be copied without express written consent. Enrollment Patterns …So we make assumptions However, instead of prescribing the exact N ij for each i and j in the simulation, I defined 9 different enrollment patterns for the 60 site/level combinations.

13  2003 Katherine L. Monti. All rights reserved. No part of this document may be copied without express written consent. Enrollment Patterns Each enrollment pattern assumed a distribution of the number of subjects in the 60 site/levels, so that there were: –30 sites, 2 levels per site –120 subjects –0-8 subjects in each of the 60 site/level strata Some enrollment patterns forced balance between the factor levels: N.1 = N.2 = 120/2 = 60

14  2003 Katherine L. Monti. All rights reserved. No part of this document may be copied without express written consent. An Enrollment Pattern EX: A simple pattern: –20 site/levels strata w/ 3 subjects –20 site/levels strata w/ 2 subjects –20 site/levels strata w/ 1 subject Total of 60 site/level strata w/ = 120 subjects Here, N ij = 1, 2 or 3 Given that pattern –The 60 strata were randomly paired to construct 30 sites. –N i1 / N i2 for site i could be any of the following: 3/3, 3/2, 3/1, 2/3, 2/2, 2/1, 1/3, 1/2, or 1/1

15  2003 Katherine L. Monti. All rights reserved. No part of this document may be copied without express written consent. Evaluation Criteria For each enrollment pattern, we want to be able to compare the treatment balance when randomization is performed WS and WLWS using permuted blocks of 4 treatments.

16  2003 Katherine L. Monti. All rights reserved. No part of this document may be copied without express written consent. Evaluation Criteria There are two types of treatment balance: –Overall balance The extent to which the treatment assignments are balanced. –Within-level balance The extent to which the treatment assignments are balanced within each of the 2 factor levels.

17  2003 Katherine L. Monti. All rights reserved. No part of this document may be copied without express written consent. Evaluation Criteria 4 criteria used to assess the randomization results of each simulated run are reported here: –N[1] = smallest N of the 4 treatments –N[1] + N[2] = smallest total sample size for any comparison of treatments –% loss of power compared to a completely balanced design for the comparison based on N[1] + N[2] for a study designed for 90% power –N[4] – N[1] = maximum difference in sample sizes

18  2003 Katherine L. Monti. All rights reserved. No part of this document may be copied without express written consent. Evaluation Criteria Overall, treatment balance would be achieved if –N1 = N2 = N3 = N4 = 120/4 = 30 –N[1] = 30 –N[1] + N[2] = 60 (No loss of power) –N[4] – N[1] = 0

19  2003 Katherine L. Monti. All rights reserved. No part of this document may be copied without express written consent. Simulation Scheme Do for enrollment pattern (EP) = 1 to 9 –Do 10,000 replications: Generate 60 strata of subjects (per EP). –Assign random numbers to each subject (to determine order of enrollment at the site and the order of enrollment in the level at the site). –Assign a random number to each stratum (to identify the levels, 1 vs 2). Randomly pair the 60 strata into 30 sites. (The stratum with the lower random number is level 1.)

20  2003 Katherine L. Monti. All rights reserved. No part of this document may be copied without express written consent. Simulation Scheme Randomly assign treatments WS based on the order of enrollment in the site, then -determine the sample size of each treatment -compute the evaluation criteria Randomly assign treatments WLWS based on the order of enrollment in the site/level, then -determine the sample size of each treatment -compute the evaluation criteria –Retain all the evaluation criteria Go to next enrollment pattern

21  2003 Katherine L. Monti. All rights reserved. No part of this document may be copied without express written consent. Results Reported For each EP there are 10,000 values of the evaluation criterion –when randomizing WS –when randomizing WLWS

22  2003 Katherine L. Monti. All rights reserved. No part of this document may be copied without express written consent.

23  2003 Katherine L. Monti. All rights reserved. No part of this document may be copied without express written consent.

24  2003 Katherine L. Monti. All rights reserved. No part of this document may be copied without express written consent.

25  2003 Katherine L. Monti. All rights reserved. No part of this document may be copied without express written consent.

26  2003 Katherine L. Monti. All rights reserved. No part of this document may be copied without express written consent.

27  2003 Katherine L. Monti. All rights reserved. No part of this document may be copied without express written consent.

28  2003 Katherine L. Monti. All rights reserved. No part of this document may be copied without express written consent. Conclusions With a relatively large number of treatments: –Randomizing within numerous small sites can lead to some treatment imbalance and loss of power. –Randomization within levels of a prognostic factor in those small sites will generally Increase the treatment imbalance overall Increase the loss of power in overall pairwise comparisons Do little to reduce the treatment imbalance within the levels of the prognostic factor

29  2003 Katherine L. Monti. All rights reserved. No part of this document may be copied without express written consent. Conclusions “When is stratification detrimental to a clinical trial design?” –I did not address this question directly. Is it the case that stratification by prognostic factor “can’t hurt”? –NO: In some cases, stratification can hurt Statistically (power) Operationally (money)

30  2003 Katherine L. Monti. All rights reserved. No part of this document may be copied without express written consent. Contact Information Slides:

* Plans were constructed with and without forcing balance between strata. No. Subjects Enrollment Plan 12*3*4* Entries are the number of strata having the indicated number of subjects.